Abstract
Clinical trials are being conducted to evaluate the safety and efficacy of hematopoietic stem cell transplantation (HSCT) as a therapy for patients with severe, refractory systemic lupus erythematosus (SLE). Nurses coordinating the care of patients receiving HSCT may be unfamiliar with aggressive systemic autoimmune diseases, such as refractory SLE. The presentations of SLE can include nephrotoxicity, pulmonary toxicity, permanent alterations in mobility, cognitive impairment, blindness, chronic pain, as well as the many complications of long term immunosuppressive therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
